Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - metformin hcl 1 g - 1 g

Armēnija - angļu - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sante s.a.s. - metformin (metformin hydrochloride) - tablets film-coated - 1000mg

Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - metformin hcl 500 mg - 500 mg

Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية النابلسي - nabulsi drug store - metformin hcl 850 mg - 850 mg

Īrija - angļu - HPRA (Health Products Regulatory Authority)

merck serono limited - metformin hydrochloride - powder for oral solution - 500 milligram

Īrija - angļu - HPRA (Health Products Regulatory Authority)

merck serono limited - metformin hydrochloride - powder for oral solution - 850 milligram

Armēnija - angļu - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sante s.a.s. - metformin (metformin hydrochloride) - tablets film-coated - 500mg

Armēnija - angļu - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sante s.a.s. - metformin (metformin hydrochloride) - tablets film-coated - 850mg

Izraēla - angļu - Ministry of Health

merck serono ltd - metformin hydrochloride - tablets prolonged release - metformin hydrochloride 1000 mg - metformin - • reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with igt* and/or ifg*, and/or increased hba1c who are:- at high risk for developing overt type 2 diabetes mellitus and- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 monthstreatment with glucophage xr must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.*igt: impaired glucose tolerance; ifg: impaired fasting glucose• treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. glucophage xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Izraēla - angļu - Ministry of Health

merck serono ltd - metformin hydrochloride - tablets prolonged release - metformin hydrochloride 500 mg - metformin - • reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with igt* and/or ifg*, and/or increased hba1c who are:- at high risk for developing overt type 2 diabetes mellitus and- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 monthstreatment with glucophage xr must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.*igt: impaired glucose tolerance; ifg: impaired fasting glucose• treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. glucophage xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.